Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Amicus Therapeutics
Biotech
Amicus pays Dimerix $30M for late-phase rare kidney disease drug
Amicus has bagged U.S. rights to the phase 3 prospect DMX-200, establishing it as a challenger to Travere Therapeutics in a rare kidney disease.
Nick Paul Taylor
May 1, 2025 10:59am
NJ biopharmas make pledge to give time off for clinical trials
Nov 20, 2024 10:00am
After phase 3 fumble, Amicus' Pompe disease drug hits new delay
May 11, 2022 10:20am
Amicus' SPAC merger folds, triggering search for $400M in cuts
Feb 24, 2022 8:10am
Amicus axes gene therapy program for type of Batten disease
Jan 10, 2022 3:20pm
FDA's vaccine office now headed by Marks—Chutes & Ladders
Oct 1, 2021 9:30am
